Evommune, Inc. (EVMN)
NYSE · USD · Healthcare · Biotechnology
$5.13 (+0.59%) as of
Key statistics
- Market cap
- 186.18M
- Forward P/E
- -1.44
- EPS (TTM)
- -3.75
- Dividend yield
- 0.00%
- 52-week range
- 4.94 – 33.20
- Revenue (TTM)
- 10M
- Profit margin
- 0.00%
- Analyst target
- $22.33
- Volume
- 322.21k
About Evommune, Inc.
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alto, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Palo Alto, CA, United States
- Employees
- 48
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.